Posted on 08/16/2021 8:50:48 PM PDT by SeekAndFind
Some 50% of the patients needed have been recruited to complete a Phase III trial of an American-developed drug that “might be a game changer” in the battle against COVID-19, says Hadassah University Medical Center’s Prof. Yosef Caraco.
Caraco told The Jerusalem Post that his team recently completed its part of a successful Phase II trial of the orally available antiviral drug candidate Molnupiravir, developed by Merck Pharmaceuticals (legally known internationally as MSD), a drug meant to slow the progression of coronavirus from mild to severe disease.
The professor presented the data from the study at the European Congress of Clinical Microbiology & Infectious Diseases in July. The study was conducted at 80 medical centers around the world in which about 300 coronavirus patients in mild or moderate condition took part. Some received Molnupiravir and others a placebo.
“The general conclusion from this stage is that, first of all, the drug is safe,” Caraco said. “We did not observe anything unusual. We also saw that those who were treated by the drug were less likely to need hospitalization compared to those who received a placebo.”
As such, he said, “We can cautiously say that the drug has the potential to prevent hospitalization if it is given to mildly or moderately ill patients, especially if given early in the course of the disease.”
The Phase II trial ran from late fall of 2020 through April 2021. The Phase III trial that started in June is expected to last another few months. Fifty percent of the patients have already been recruited, Caraco said.
He added that the drug is active against the coronavirus and can stop infection from progressing from mild or moderate to severe. “Up until now, we have been very busy trying to research drugs to treat the most severe patients in the hospital,” Caraco said. “This is quite obvious because we are speaking about people at risk of death.”
However, he said that after all this time, the results have not been encouraging. While doctors are using a cocktail of drugs to treat severe COVID-19, what they found is that the most important aspect in the prognosis of these patients is the level of intensive care treatment that they can provide.
“The success rate of all of these drugs we have been trying is really disappointing,” he said.
Molnupiravir is an effort to change the course of treatment, turning attention to the nearly 90% of COVID patients that are in mild or moderate condition.
“The idea is that if we can treat them, we can prevent the progression to severe disease,” Caraco explained. “This is a total change in the way we are trying to tackle the disease. This is a paradigm change.”
The Phase III study involves many more patients. Caraco said it has been challenging to reach these patients in Israel, as many have already been vaccinated and therefore do not qualify for the study. In addition, most patients who have mild symptoms think they can “take Tylenol and tea” and the virus will disappear on its own.
“The average mild patient thinks, ‘Why should I get any treatment? I was told this is a simple and easy disease,’” Caraco explained. But he said that if the Phase III trial validates the findings of the Phase II trial, “this is going to be a game changer… When there is a plague, the most important and efficient way to struggle against it is to prevent it. That is why we are giving so much attention to the vaccines. But the vaccines are not 100% foolproof. The next best thing to preventing infection is preventing deterioration.”
He said the research team also hypothesizes that the drug could help reduce the contagiousness of the patients and therefore the likelihood of their spreading the virus to household contacts. They also believe it might have a positive impact on preventing long COVID.
“If we can avoid deterioration to a more severe disease,” Caraco concluded, “this could also alleviate the fear of these patients ending up in the hospital as severe patients.”
Begs the question why such an obvious and previously available treatment was not ushered forward from the beginning.
Yeah, you would think all the antivirals would have been tested quickly.
I still think they should test all of the coronvirus cold viruses to see if any of them give full or partial immunity.
Meanwhile many US Doctors have been treating their patients very successfully for over a year with a few different protocols.
But everyone needs the mRNA jab NOW!
No. This must be hidden. Don’t you realize that Democrats/media/woke corporations/academia/hollywood need more time to correctly program citizens? All hopeful reports must be quashed. Folks will begin to think they can just walk up to the polls to vote come election time. People must be kept in fear for at least one more election season to complete the takeover of the globe. Trucked in ballots will be needed one more time.
Try Ivermectin Israel.
RE: Try Ivermectin Israel.
Merck, the developer of this drug, Molnupiravir ( being presented here ), was the manufacturer of Ivermectin. The patent for Ivermectin expired nearly 30 years ago and became a generic drug, therefore, Merck cannot make money off it.
Hence, this new drug — Molnupiravir ( and Merck’s OPENLY discouraging the use of Ivermectin for Covid ).
Let me guess.
They tweaked Ivermectin and renamed it and voila, new miracle prophylactic cure for COVID.
Eighteen months to figure out that you just might want to attempt to treat patients before they are critical? Novel concept...what a game changer for the world of medicine!
THAT is exactly what they did BANK ON IT!!!
Sorry, not needed.
Simply use the cheap, already tested Ivermectin or HCQ and the problem is solved.
No need to pay Big PHARMA billions of dollars.
Amazing tax savings and quicker and more complete solution to the problem at hand.
This drug was developed by a research team at Emory University in Atlanta. They were confident they had an effective drug way back when the covid thing first began and made a deal with Merck. But it was difficult to find enough volunteers to test the drug properly and it took a long time to just get to this point.
It’s probably Ivermectin with an extra hydroxyl group, or something.
As long as it works and I don’t have to pay excessive amounts for it, I’ll take it.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.